Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) FCF Margin (2016 - 2025)

Vistagen Therapeutics' FCF Margin history spans 11 years, with the latest figure at 5867.66% for Q4 2025.

  • For Q4 2025, FCF Margin fell 143048.0% year-over-year to 5867.66%; the TTM value through Dec 2025 reached 7639.11%, down 203493.0%, while the annual FY2025 figure was 8662.55%, 623379.0% down from the prior year.
  • FCF Margin for Q4 2025 was 5867.66% at Vistagen Therapeutics, down from 5340.31% in the prior quarter.
  • Across five years, FCF Margin topped out at 66413.33% in Q1 2025 and bottomed at 12989.29% in Q2 2024.
  • The 4-year median for FCF Margin is 4437.18% (2024), against an average of 578.47%.
  • The largest annual shift saw FCF Margin crashed -904379bps in 2024 before it surged 6995920bps in 2025.
  • A 4-year view of FCF Margin shows it stood at 4978.46% in 2021, then soared by 77bps to 1159.37% in 2023, then crashed by -283bps to 4437.18% in 2024, then plummeted by -32bps to 5867.66% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's FCF Margin are 5867.66% (Q4 2025), 5340.31% (Q3 2025), and 7717.21% (Q2 2025).